Matches in SemOpenAlex for { <https://semopenalex.org/work/W2734502164> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2734502164 abstract "Introduction: In July 2015, the FDA approved alirocumab (ALI), a first in class PCSK9-inhibitor indicated for cholesterol lowering as adjunct to diet and maximum tolerated statin therapy for adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of low-density lipoprotein cholesterol (LDL-C). Furthermore, in March 2016, the ACC released the expert consensus pathway on the role of non-statin therapies in LDL-C reduction. To understand early prescribing patterns, this study aims to describe the types of patients (pts) prescribed ALI. Methods: All adult pts with a written prescription (Rx) of ALI were included from Accenture’s Predictive Health Intelligence Environment dataset consisting of electronic medical records from 26 integrated delivery networks (IDN). Pts were further required to have one encounter with the IDN within 12 months prior to the first Rx of ALI (index), used to classify pts’ other lipid modifying treatment (LMT) and past medical history. Probable HeFH pts were identified using either the modified Dutch Lipid Criteria Network (score ≥ 6) or an LDL-C ≥190 mg/dL. Results: Among the 564 pts who met study criteria as of May 18, 2016, 69% had ASCVD, 13% were probable HeFH, and 18% were not identified as ASCVD or HeFH. The average age was 65.9 years (SD 10.1), 51% were male, and 74% Caucasian. About 79% had hypertension, 32% had diabetes, 14% had chronic kidney disease and 28% had a history of smoking. Prior to the ALI Rx, for those pts with an LDL-C value, the mean was 135.0 mg/dL (SD 57.5) with 72% having an LDL-C >100 mg/dL. About 72% of the pts had evidence of LMT during the prior 12 months to index; conversely, 28% of pts did not in the same period. Of those with LMT in this period, 29% were on high-intensity statins. Ezetimibe rxs were seen in 31% of pts with LMT, either alone or in combination with statins. Cardiologists were the specialists who prescribed ALI most often (43.1%). Conclusions: ALI was predominantly prescribed in pts with ASCVD whose LDL-C was high and far from clinical goals. In light of the new ACC consensus pathway for non-statins, there is still a large population of high-risk pts who have unmet lipid lowering needs and would benefit from alirocumab." @default.
- W2734502164 created "2017-07-21" @default.
- W2734502164 creator A5003254447 @default.
- W2734502164 creator A5008125928 @default.
- W2734502164 creator A5021274752 @default.
- W2734502164 creator A5033195573 @default.
- W2734502164 creator A5068662580 @default.
- W2734502164 creator A5087432256 @default.
- W2734502164 date "2016-11-11" @default.
- W2734502164 modified "2023-09-23" @default.
- W2734502164 title "Abstract 17012: Who is Today’s Alirocumab Patient? A Real World Perspective of Patients Prescribed Alirocumab in the United States" @default.
- W2734502164 hasPublicationYear "2016" @default.
- W2734502164 type Work @default.
- W2734502164 sameAs 2734502164 @default.
- W2734502164 citedByCount "0" @default.
- W2734502164 crossrefType "journal-article" @default.
- W2734502164 hasAuthorship W2734502164A5003254447 @default.
- W2734502164 hasAuthorship W2734502164A5008125928 @default.
- W2734502164 hasAuthorship W2734502164A5021274752 @default.
- W2734502164 hasAuthorship W2734502164A5033195573 @default.
- W2734502164 hasAuthorship W2734502164A5068662580 @default.
- W2734502164 hasAuthorship W2734502164A5087432256 @default.
- W2734502164 hasConcept C126322002 @default.
- W2734502164 hasConcept C2426938 @default.
- W2734502164 hasConcept C2776839432 @default.
- W2734502164 hasConcept C2778163477 @default.
- W2734502164 hasConcept C2779120738 @default.
- W2734502164 hasConcept C2779134260 @default.
- W2734502164 hasConcept C2780072125 @default.
- W2734502164 hasConcept C2780745583 @default.
- W2734502164 hasConcept C2780902209 @default.
- W2734502164 hasConcept C2780948078 @default.
- W2734502164 hasConcept C2909478654 @default.
- W2734502164 hasConcept C43554185 @default.
- W2734502164 hasConcept C71924100 @default.
- W2734502164 hasConcept C98274493 @default.
- W2734502164 hasConceptScore W2734502164C126322002 @default.
- W2734502164 hasConceptScore W2734502164C2426938 @default.
- W2734502164 hasConceptScore W2734502164C2776839432 @default.
- W2734502164 hasConceptScore W2734502164C2778163477 @default.
- W2734502164 hasConceptScore W2734502164C2779120738 @default.
- W2734502164 hasConceptScore W2734502164C2779134260 @default.
- W2734502164 hasConceptScore W2734502164C2780072125 @default.
- W2734502164 hasConceptScore W2734502164C2780745583 @default.
- W2734502164 hasConceptScore W2734502164C2780902209 @default.
- W2734502164 hasConceptScore W2734502164C2780948078 @default.
- W2734502164 hasConceptScore W2734502164C2909478654 @default.
- W2734502164 hasConceptScore W2734502164C43554185 @default.
- W2734502164 hasConceptScore W2734502164C71924100 @default.
- W2734502164 hasConceptScore W2734502164C98274493 @default.
- W2734502164 hasLocation W27345021641 @default.
- W2734502164 hasOpenAccess W2734502164 @default.
- W2734502164 hasPrimaryLocation W27345021641 @default.
- W2734502164 hasRelatedWork W2073792086 @default.
- W2734502164 hasRelatedWork W2414368128 @default.
- W2734502164 hasRelatedWork W2767072068 @default.
- W2734502164 hasRelatedWork W2787480145 @default.
- W2734502164 hasRelatedWork W2790951009 @default.
- W2734502164 hasRelatedWork W2885595282 @default.
- W2734502164 hasRelatedWork W2892320798 @default.
- W2734502164 hasRelatedWork W2946215404 @default.
- W2734502164 hasRelatedWork W2947865345 @default.
- W2734502164 hasRelatedWork W2960453033 @default.
- W2734502164 hasRelatedWork W2983052551 @default.
- W2734502164 hasRelatedWork W2989910051 @default.
- W2734502164 hasRelatedWork W3016409621 @default.
- W2734502164 hasRelatedWork W3033787656 @default.
- W2734502164 hasRelatedWork W3035573825 @default.
- W2734502164 hasRelatedWork W3045930668 @default.
- W2734502164 hasRelatedWork W3093343388 @default.
- W2734502164 hasRelatedWork W3135127450 @default.
- W2734502164 hasRelatedWork W3162552042 @default.
- W2734502164 hasRelatedWork W3201142270 @default.
- W2734502164 hasVolume "134" @default.
- W2734502164 isParatext "false" @default.
- W2734502164 isRetracted "false" @default.
- W2734502164 magId "2734502164" @default.
- W2734502164 workType "article" @default.